References
- World Health Organization. Global eradication of poliomyelitis by the year 2000 [Internet]. Report No.: WHA41.28. Geneva: World Health Organization; 1988 May. [cited 2015 Mar 27]. Available from: http://www.polioeradication.org/content/publications/19880513_resolution.pdf
- Global Polio Eradication Initiative > Data and monitoring > Polio this week > Wild poliovirus list [Internet]. [cited 2015 Apr 22]. Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx
- Global eradication of wild poliovirus type 2 declared [Internet]. Global Polio Eradication Initiative > News stories. 2015. [cited 2015 Oct 6]. Available from: http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx
- Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001 Mar 30;50(12):222–224.
- Thompson KM, Tebbens RJD. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines. 2012 Apr 1;11(4):449–459.
- Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991 Sep;13(5):926–939.
- Sutter RW, Kew OM, Cochi SL, et al. 28 - Poliovirus vaccine—live.In:Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines (Sixth Edition) [Internet]. London: W.B. Saunders; 2013. p. 598–645. Available from: http://www.sciencedirect.com/science/article/pii/B9781455700905000355
- Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014 Nov 1;210(suppl 1):S380–9.
- Duintjer Tebbens RJ, Pallansch MA, Kim J-H, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;33(4):680–702.
- Iqbal S, Shi J, Seib K, et al. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12. Lancet Infect Dis. 2015 Oct;15(10):1175–1182.
- World Health Organization. Global advisory committee on vaccine safety, 11-12 december 2013. Wkly Epidemiol Rec. 2014;7(89):53–60.
- Stratton KR, Howe CJ, Johnston RB. Adverse events associated with childhood vaccines other than pertussis and rubella: summary of a report from the Institute of Medicine. JAMA. 1994;271(20):1602–1605.
- Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599.
- Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis. 1991 Jan;163(1):1–6.
- Kapusinszky B, Molnar Z, Szomor KN, et al. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol. 2010 Mar;58(2):211–217.
- Patel M, Zipursky S, Orenstein W, et al. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749–762.
- World Health Organization. Report of the SAGE Polio Working Group Meeting 7-8 September 2015 [Internet]. Geneva: World Health Organization. [cited 2015 Oct 26]. Available from: http://www.who.int/immunization/sage/meetings/2015/october/2_SAGE_WG_report_draft_Final_clean.pdf?ua=1
- Global Polio Eradication Initiative > Data and monitoring > Polio this week > Circulating vaccine-derived poliovirus [Internet]. [cited 2015 Apr 6]. Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx
- Bandyopadhyay AS, Garon J, Seib K, et al. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808.
- Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis [Internet]. 2015 Sep 17;15. [cited 2015 Oct 5]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574397/
- Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018 [Internet]. 2013. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf
- World Health Organization. Meeting of the strategic advisory group of experts on immunization, october 2015 - conclusions and recommendations [Internet]. Report No.: 50. Geneva: World Health Organization; 2015 Dec. p. 681–700. [cited 2015 Dec 17]. Available from: http://www.who.int/wer/2015/wer9050.pdf
- Estívariz CF, Anand A, Gary HE Jr, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis [Internet]. [cited 2015 Jul 1]. Available from: HYPERLINK “http://www.sciencedirect.com/science/article/pii/S1473309915000948” http://www.sciencedirect.com/science/article/pii/S1473309915000948
- Grassly NC. New vaccine strategies to finish polio eradication. Lancet Infect Dis [Internet]. [cited 2015 Jul 1]. Available from: http://www.sciencedirect.com/science/article/pii/S1473309915000924
- Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010 Nov 13;376(9753):1682–1688.
- John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet. 2014 Oct 31;384(9953):1505–1512.
- Jafari H, Deshpande JM, Sutter RW, et al. Efficacy of inactivated poliovirus vaccine in India. Science. 2014 Aug 22;345(6199):922–925.
- Saleem AF, Mach O, Quadri F, et al. Immunogenicity of poliovirus vaccines in chronically malnourished infants: A randomized controlled trial in Pakistan. Vaccine. 2015 Jun 4;33(24):2757–2763.
- O’Ryan M, Bandyopadhyay AS, Villena R, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis [Internet]. 2015 Aug 27. [cited 2015 Sep 11]. Available from: http://www.sciencedirect.com/science/article/pii/S1473309915002194
- Sutter RW, Bahl S, Deshpande J, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled clinical trial. Lancet [Internet]. 2015 Sep 18. doi:10.1016/S0140-6736(15)61521-5
- Lu L, Li X, Zhang H, et al. Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants. Vaccine. 2015 Aug 26;33(36):4653–4658.
- Wright PF, Wieland-Alter W, Ilyushina NA, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis [Internet]. 2014 Jan 23. Available from: http://jid.oxfordjournals.org/content/early/2014/01/23/infdis.jit671.abstract
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine - Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 9]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01831050?term=%22inactivated+polio+vaccine%22&rank=16
- Immunogenicity of Inactivated and Live Polio Vaccines - Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 9]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01813604?term=%22inactivated+polio+vaccine%22&rank=5
- Tebbens RJD, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–1505.
- World Health Organization. Cessation of routine oral polio vaccine (OPV) use after global polio eradication. Framework for national policy makers in OPV-using countries. Report No.: (WHO/POLIO/05.02). Geneva: World Health Organization; 2005.
- Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med. 2008;10(8):190.
- Hampton L Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine — worldwide, 2013–2016 [Internet]. Report No.: 25. Centers for Disease Control and Prevention; 2015 Jul. p. 699–702. [cited 2015 Aug 25]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6425a4.htm
- Thompson KM, Tebbens RJD. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014 Nov 1;210(suppl 1):S475–84.
- WHO | The scientific rationale for IPV introduction and OPV withdrawal [Internet]. WHO. [cited 2015 Dec 15]. Available from: http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/rationale/en/index8.html
- Lago PM, Cáceres VM, Galindo MA, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol. 2001 Oct 1;30(5):1029–1034.
- Huang QS, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet. 2005 Aug 30;366(9483):394–396.
- Lago PM, Gary HE, Pérez LS, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol. 2003 Oct 1;32(5):772–777.
- Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014 Nov 1;210(Suppl 1):S485S497.
- Current OPV Supply and Outlook [Internet]. UNICEF. 2013 Jul [cited 2015 Jul 7]. Available from: http://www.unicef.org/supply/files/Oral_polio_vaccine_update.pdf
- Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis [Internet]. 2015 Sep 24;15. [cited 2015 Oct 5]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582932/
- Wood DJ, Sutter RW, Dowdle WR. Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Organ. 2000 Mar;78(3):347–357.
- McKinlay MA, Collett MS, Hincks JR, et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis. 2014 Nov 1;210(suppl 1):S447S453.
- Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis [Internet]. 2015 Sep 17;15. [cited 2015 Oct 5]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574619/
- Melnick JL, Berencsi G, Biberi-Moroeanu S, et al. WHO collaborative studies on poliovirus type 3 strains isolated during the 1968 poliomyelitis epidemic in Poland. Bull World Health Organ. 1972;47(3):287.
- Martın J, Ferguson GL, Wood DJ, et al. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology. 2000 Dec 5;278(1):42–49.
- Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res. 2003 Dec;118:217–223.
- Dowdle W, Van Der Avoort H, De Gourville E, et al. Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal Off Publ Soc Risk Anal. 2006 Dec;26(6):1449–1469.
- Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis. 1997 Feb 1;175(Supplement 1):S286S292.
- Poliomyelitis: intensification of the global eradication initiative [Internet]. 2014 Mar. [cited 2014 Oct 7]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_38-en.pdf
- World Health Organization. Weekly epidemiological record. polio vaccines: WHO position paper, January 2014 [Internet]. Report No.: 9.. Geneva: World Health Organization; 2014 Feb. p. 73–92. Available from: http://www.who.int/wer/2014/wer8909.pdf?ua=1
- WHO | IPV Introduction, OPV Withdrawal and Routine Immunization Strengthening [Internet]. WHO. [cited 2015 Sep 14]. Available from: http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/en/
- World Health Assembly. Agenda Item 15.2 poliomyelitis. Geneva:World Health Organization; 2015. cited 2015 Jun 18. Available from http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R3-en.pdf
- Operational Framework for monovalent oral poliovirus type 2 (mOPV2) deployment and replenishment (during the endgame period) [Internet]. Global Polio Eradication Initiative; 2015 Jan. [cited 2015 Sep 1]. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/mOPV2_Operational_Framework.pdf
- Responding to a poliovirus outbreak Standard Operating Procedures for a new polio outbreak in a polio-free country [Internet]. Global Polio Eradication Initiative. 2015. [cited 2015 Sep 15]. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/PolioEradicators/1a.PolioOutbreakGuideline20150220.pdf
- GAPIII-WHO global action plan to minimize poliovirus facility-associated risk. [Internet]. Geneva, Switzerland: World Health Institution. 2014. [cited 2015 Jun 22]. Available from: https://www.google.com/search?q=polio+containment+GAP+III¡utf-8œutf-8
- World Health Organization Guidelines for Containment of Poliovirus Following Type-Specific Polio Eradication — worldwide. 2015. [Internet]. [cited 2015 Oct 20]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6433a5.htm?s_cid=mm6433a5_w
- Summary of the October 2015 meeting of the Strategic Advisory Group of Experts on immunization (SAGE) [Internet]. [cited 2015 Oct 26]. Available from: http://www.who.int/immunization/sage/meetings/2015/october/sage_report_oct_2015.pdf?ua=1
- Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations [Internet]. World Health Organization. 2015 May. p. 261–280. [cited 2015 Jun 15]. Available from: http://www.who.int/immunization/sage/meetings/2015/april/en/
- Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis [Internet]. 2015 Sep 17;15. [cited 2015 Oct 5]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574692/
- Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis [Internet]. 2015 Sep 24;15. [cited 2015 Oct 5]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582727/
- Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal [Internet]. 2012 Jul 15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22804479
- Organization WH, others. Governing body matters: Key issues arising out of the Sixty-eighth World Health Assembly and the 136th and 137th sessions of the WHO Executive Board. 2015 [cited 2015 Nov 4]; Available from: http://apps.who.int/iris/handle/10665/180798
- SEARO | WHO South-East Asia Region certified polio-free [Internet]. SEARO. [cited 2015 Feb 26]. Available from: http://www.searo.who.int/mediacentre/releases/2014/pr1569/en/
- Nair H, Hazarika I, Patwari A. A roller-coaster ride: Introduction of pentavalent vaccine in India. J Glob Health. 2011 Jun;1(1):32–35.
- John TJ, Vashishtha VM. Eradicating poliomyelitis: India’s journey from hyperendemic to polio-free status. Indian J Med Res. 2013 May;137(5):881–894.
- Paul Y. OPV cannot eradicate polio from India: Do we need any further evidence? Vaccine. 2008 Apr 16;26(17):2058–2061.
- Pallansch MA, Sandhu HS. The eradication of polio — progress and challenges. N Engl J Med. 2006 Dec 14;355(24):2508–2511.
- Polio-Free Certification and Lessons Learned — South-East Asia Region, March 2014 [Internet]. [cited 2015 Feb 26]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6342a2.htm
- Cochi SL, Freeman A, Guirguis S, et al. Global Polio Eradication Initiative: Lessons Learned and Legacy. J Infect Dis. 2014 Nov 1;210(suppl 1):S540–S546.
- Heymann DL, Chen L, Takemi K, et al. Global health security: the wider lessons from the west African Ebola virus disease epidemic. Lancet. 2015 May 15;385(9980):1884–1901.
- Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2010 Dec;29(2):334–343.